RGTA-based matrix therapy in severe experimental corneal lesions: Safety and efficacy studies

Brignole-Baudouin, Françoise; Warnet, Jean‐Michel; Barritault, Denis

doi:10.1016/j.jfo.2013.01.012

Cited by 45 publications

(38 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,13 Histological studies have shown several effects of the RGTA (Cacicol20) including amelioration of tissue edema, fibrosis, and inflammation, thereby improving wound repair. 14,15 Our study findings indicate that the RGTA (Cacicol20) could possibly promote-accelerate the reepithelialization process after CXL treatment. Moreover, this is the first study that compares the RGTA (Cacicol20) effect on nonpathological corneal epithelium, in addition to previously published articles that described the effect of the agent in pathological conditions such as neurotrophic ulcers and PEDs.…”

Section: Discussionmentioning

confidence: 73%

Effect of the Regenerative Agent Poly(Carboxymethylglucose Sulfate) on Corneal Wound Healing After Corneal Cross-Linking for Keratoconus

Kymionis

Liakopoulos

Grentzelos

et al. 2015

Cornea

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 73%

Effect of the Regenerative Agent Poly(Carboxymethylglucose Sulfate) on Corneal Wound Healing After Corneal Cross-Linking for Keratoconus

Kymionis

Liakopoulos

Grentzelos

et al. 2015

Cornea

View full text Add to dashboard Cite

show abstract

“…11,12 One recent study in a rabbit corneal model concluded that RGTA-based matrix therapy not only provided reepithelialization, but also reduced clinical signs of inflammation and improved histological patterns such as edema, fibrosis, neovascularization, and inflammation. 26 There is currently limited data on the effect of RGTAs on corneal wound healing with different etiologies. Chebbi et al evaluated the tolerance and safety of a new ophthalmic solution based on RGTA technology in corneal ulcers and severe chronic dystrophies.…”

Section: Discussionmentioning

confidence: 99%

A New Matrix Therapy Agent for Faster Corneal Healing and Less Ocular Discomfort Following Epi-off Accelerated Corneal Cross-linking in Progressive Keratoconus

Gümüş¹,

Guerra²,

Marques³

et al. 2017

J Refract Surg

View full text Add to dashboard Cite

PURPOSE: To investigate the hypothesis that a new matrix therapy agent (ReGeneraTing Agent, [RGTA]) would speed up the corneal reepithelialization, improve stromal healing, and reduce ocular symptoms after epi-off corneal cross-linking (CXL). METHODS: Sixty eyes of 60 patients with progressive keratoconus were enrolled in the study. Epi-off accelerated CXL was performed in all patients. Sixty eyes were randomized into two groups according to use of RGTA eye drops prior to contact lens fitting at the end. Identical medical agents were started postoperatively for the two groups. All participants were monitored on 3 consecutive days after the CXL. Ocular pain, burning, stinging, tearing, photophobia, conjunctival hyperemia, and corneal healing status were evaluated. RESULTS: By day 2, 25 eyes (83.3%) with RGTA revealed complete healing compared to 4 eyes (13.3%) that revealed complete healing in the control group ( P < .001). All eyes had complete corneal epithelial defect closure by day 3 in both groups. Ocular pain scores were lower in the RGTA group on days 0, 1, and 2 (all P < .05). Burning scores were lower on days 1 and 2; stinging scores on days 2 and 3; tearing scores on days 2 and 3; and photophobia on days 1 and 2 ( P < .05) in the RGTA group compared to the control group. CONCLUSIONS: RGTA ophthalmic solution facilitates corneal healing by reconstructing the extracellular matrix in the wound area, leading to an earlier relief of symptoms for patients. [ J Refract Surg. 2017;33(3):163–170.]

show abstract

“…[27] Burn-related skin fibrosis-Normalization of collagen III/I levels.-Increased activity of MMP-2 and MMP-9.Garcia-Filipe [28] Cornea Corneal alkali burn-Enhanced re-epithelialization.-Reduction in ocular inflammation.-Histological changes (reduced edema, fibrosis, blood vessels, inflammatory cells).Brignole-Baudouin et al . [29] Corneal alkali burn-Decreased corneal inflammation.-Enhanced re-epithelialization.-Decreased neovascularization.-Healing of corneal ulcers following application 1 month post-injury.Cejkova et al . [30] Post-surgical corneal ulcers-Increased corneal transparency.-Increased corneal thickness and epithelial cell organization.-Decreased myofibroblasts.-Increased nerve terminal density.Riestra [31] Oral and Digestive Tract 5-fluorouracil induced mucositis-Prevention of mucositis and reduction of area and thickness of lesions.-Protection of basement membrane.Morvan et al .…”

Section: Rgta® Pre-clinical Modelsmentioning

confidence: 99%

RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

et al. 2016

View full text Add to dashboard Cite

The importance of extracellular matrix (ECM) integrity in maintaining normal tissue function is highlighted by numerous pathologies and situations of acute and chronic injury associated with dysregulation or destruction of ECM components. Heparan sulfate (HS) is a key component of the ECM, where it fulfils important functions associated with tissue homeostasis. Its degradation following tissue injury disrupts this delicate equilibrium and may impair the wound healing process. ReGeneraTing Agents (RGTA®s) are polysaccharides specifically designed to replace degraded HS in injured tissues. The unique properties of RGTA® (resistance to degradation, binding and protection of ECM structural and signaling proteins, like HS) permit the reconstruction of the ECM, restoring both structural and biochemical functions to this essential substrate, and facilitating the processes of tissue repair and regeneration. Here, we review 25 years of research surrounding this HS mimic, supporting the mode of action, pre-clinical studies and therapeutic efficacy of RGTA® in the clinic, and discuss the potential of RGTA® in new branches of regenerative medicine.

show abstract

RGTA-based matrix therapy in severe experimental corneal lesions: Safety and efficacy studies

Cited by 45 publications

References 46 publications

Effect of the Regenerative Agent Poly(Carboxymethylglucose Sulfate) on Corneal Wound Healing After Corneal Cross-Linking for Keratoconus

Effect of the Regenerative Agent Poly(Carboxymethylglucose Sulfate) on Corneal Wound Healing After Corneal Cross-Linking for Keratoconus

A New Matrix Therapy Agent for Faster Corneal Healing and Less Ocular Discomfort Following Epi-off Accelerated Corneal Cross-linking in Progressive Keratoconus

RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

Contact Info

Product

Resources

About